Abdelkader Rahmaoui

Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.

K. Rothman, C. Iribarren, E. Guinan, 2014, The Journal of allergy and clinical immunology.

Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma

K. Rothman, T. Omachi, M. Farkouh, 2017, The Journal of allergy and clinical immunology.

Omalizumab and malignancy: Interim results from the EXCELS study

M. Eisner, M. K. Miller, W. Chou, 2011 .

Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study.

P. Lieberman, D. Umetsu, G. Carrigan, 2016, The Journal of allergy and clinical immunology.

The safety and interpretability of skin tests with omalizumab.

P. Lieberman, Abdelkader Rahmaoui, D. Wong, 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study.

S. Spector, C. Bindslev‐Jensen, J. Grob, 2015, The Journal of investigative dermatology.

Erratum: Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: A randomized, placebo-controlled study (Journal of Investigative Dermatology (2015) 135 (67-75)) DOI: 10.1038/jid.2014.306)

S. Spector, C. Bindslev‐Jensen, J. Grob, 2015 .

Adolescent boys with constitutional delay of growth and puberty grow faster than patients with organic growth hormone deficiency

T. Reinehr, G. Binder, G. Blumenstock, 2020, Clinical endocrinology.

Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product

V. Quarmby, M. Vanderlaan, R. Olney, 2019, Clinical pharmacology and therapeutics.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study

S. Spector, C. Bindslev‐Jensen, J. Grob, 2014, The Journal of investigative dermatology.

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic / Spontaneous Urticaria Who Remain Symptomatic on H 1 Antihistamines : A Randomized , Placebo-Controlled Study

S. Spector, C. Bindslev‐Jensen, J. Grob, 2010 .

Baseline characteristics of patients enrolled in EXCELS: a cohort study.

S. Szefler, J. Fish, S. Tilles, 2009, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.